DE69733247D1 - Humanisiertes grünes-fluoreszenzprotein und methoden - Google Patents

Humanisiertes grünes-fluoreszenzprotein und methoden

Info

Publication number
DE69733247D1
DE69733247D1 DE69733247T DE69733247T DE69733247D1 DE 69733247 D1 DE69733247 D1 DE 69733247D1 DE 69733247 T DE69733247 T DE 69733247T DE 69733247 T DE69733247 T DE 69733247T DE 69733247 D1 DE69733247 D1 DE 69733247D1
Authority
DE
Germany
Prior art keywords
humanized
mammalian cells
methods
green fluorescence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733247T
Other languages
English (en)
Other versions
DE69733247T2 (de
Inventor
Sergei Zolotukhin
Nicholas Muzyczka
W Hauswirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of DE69733247D1 publication Critical patent/DE69733247D1/de
Application granted granted Critical
Publication of DE69733247T2 publication Critical patent/DE69733247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69733247T 1996-01-18 1997-01-17 Humanisiertes grünes-fluoreszenzprotein und methoden Expired - Lifetime DE69733247T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/588,201 US5874304A (en) 1996-01-18 1996-01-18 Humanized green fluorescent protein genes and methods
US588201 1996-01-18
PCT/US1997/000755 WO1997026333A1 (en) 1996-01-18 1997-01-17 Humanized green fluorescent protein genes and methods

Publications (2)

Publication Number Publication Date
DE69733247D1 true DE69733247D1 (de) 2005-06-16
DE69733247T2 DE69733247T2 (de) 2006-01-19

Family

ID=24352898

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733247T Expired - Lifetime DE69733247T2 (de) 1996-01-18 1997-01-17 Humanisiertes grünes-fluoreszenzprotein und methoden

Country Status (9)

Country Link
US (2) US5874304A (de)
EP (1) EP0874903B1 (de)
JP (2) JP4229469B2 (de)
AT (1) ATE295416T1 (de)
AU (1) AU730842B2 (de)
CA (1) CA2243088C (de)
DE (1) DE69733247T2 (de)
NZ (1) NZ330957A (de)
WO (1) WO1997026333A1 (de)

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6020192A (en) * 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
AR006928A1 (es) * 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
US6124128A (en) * 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US6593135B2 (en) 1996-08-16 2003-07-15 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Long wavelength engineered fluorescent proteins
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US6670449B1 (en) 1997-02-13 2003-12-30 Memorial Sloan-Kettering Cancer Center Hybrid molecules and their use for optically detecting changes in cellular microenvironments
PT1199564E (pt) * 1997-04-07 2004-10-29 Bioimage A S Um metodo para rastrear substancias que tem um efeito na translocacao intracelular
US6046925A (en) * 1997-04-14 2000-04-04 The Regents Of The University Of California Photochromic fluorescent proteins and optical memory storage devices based on fluorescent proteins
US6528307B1 (en) * 1997-04-25 2003-03-04 The Wistar Institute Of Anatomy And Biology Cytolytic T-cell clones against colorectal carcinoma
US6232523B1 (en) * 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6251384B1 (en) 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
AUPP807899A0 (en) * 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO1999002694A1 (en) * 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6602677B1 (en) * 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6130313A (en) * 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
JP3736617B2 (ja) * 1997-12-12 2006-01-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞型の決定方法
DE19811618C1 (de) * 1998-03-17 2000-08-31 Andreas Jenne Ribozym codierende DNA und ein Oligonucleotidsubstrat enthaltende Zusammensetzung und Verfahren zur Messung von Transkriptionsraten
AU3366099A (en) * 1998-03-26 1999-10-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Drm, a secreted protein with cell growth inhibiting activity, and related methods and compositions
EP1925320A3 (de) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferasen, fluoreszierende Proteine, Nukleinsäuren zur Kodierung der Luciferasen und der fluoreszierenden Proteine sowie deren Verwendung zur Diagnose, zum Screening mit hohem Durchsatz und zur Behandlung neuartiger Probleme
DE69938293T2 (de) 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
FR2778408A1 (fr) * 1998-05-11 1999-11-12 Univ Pasteur Anticorps recombinants fluorescents
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
GB9810752D0 (en) * 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US6509174B2 (en) * 1998-06-16 2003-01-21 Ecole Polytechnique Federal De Lausanne (Epfl) Cells, genetically modified with optical marker
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
US9834584B2 (en) * 1998-12-11 2017-12-05 Takara Bio Usa, Inc. Nucleic acids encoding chromophores/fluorophores and methods for using the same
US7338783B2 (en) 1998-12-11 2008-03-04 Clontech Laboratories, Inc. Nucleic acids encoding chromophores/fluorophores and methods for using the same
US20030087492A1 (en) 2001-11-02 2003-05-08 Promos Technologies, Inc. Semiconductor device and method of manufacturing the same
AUPP807799A0 (en) * 1999-01-08 1999-02-04 University Of Queensland, The Polynucleotide and method
US8885913B2 (en) 1999-01-25 2014-11-11 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
US7450229B2 (en) 1999-01-25 2008-11-11 Amnis Corporation Methods for analyzing inter-cellular phenomena
US8406498B2 (en) 1999-01-25 2013-03-26 Amnis Corporation Blood and cell analysis using an imaging flow cytometer
US8131053B2 (en) 1999-01-25 2012-03-06 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
EP1157126A4 (de) * 1999-02-24 2005-03-02 Gen Hospital Corp Verfahren zum klonen von zwischenprodukten für signaltransduktion
DE19915137C2 (de) * 1999-03-26 2001-10-18 Michael Schaefer Verfahren zur Quantifizierung mehrerer Fluorochrome in einer mehrfach gefärbten Probe bei der Fluoreszenzmikroskopie und Verwendungen des Verfahrens
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
EP1196566B1 (de) * 1999-07-12 2006-02-01 Genentech, Inc. Expressionsvektoren und anwendungsmethoden
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
US6716614B1 (en) 1999-09-02 2004-04-06 Lexicon Genetics Incorporated Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
MXPA02004954A (es) * 1999-11-19 2003-02-27 Cold Spring Harbor Lab Proteina fluorescente de expresion en ratones transgenicos bajo el control del promotor de nestina.
US7468277B2 (en) * 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
US20020064842A1 (en) * 2000-06-09 2002-05-30 Sorge Joseph A. Renilla reniformis green fluorescent protein and mutants thereof
US6502774B1 (en) * 2000-03-08 2003-01-07 J + L Fiber Services, Inc. Refiner disk sensor and sensor refiner disk
US7109315B2 (en) * 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
CA2301158A1 (en) * 2000-03-24 2001-09-24 Stephen J. Allen Screening methods for compounds useful for modulating lipid metabolism in disease
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JP2002045174A (ja) * 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
KR100393709B1 (ko) * 2000-08-07 2003-08-06 광주과학기술원 재조합 동물 세포주를 이용한 환경 오염 물질의 탐지 방법
KR100403159B1 (ko) * 2000-08-07 2003-10-30 광주과학기술원 씨-포스 프로모터와 녹색 형광 단백질 유전자의 융합유전자, 이 유전자를 포함하는 벡터 및 이 벡터로형질감염된 재조합 동물 세포
JP2004267001A (ja) * 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
US20030157643A1 (en) * 2000-08-24 2003-08-21 Almond Brian D Synthetic nucleic acids from aquatic species
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US20040115659A1 (en) * 2001-08-29 2004-06-17 Benjamin Geiger Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
WO2002030965A2 (en) * 2000-10-12 2002-04-18 Clontech Laboratories, Inc. Nucleic acids encoding stichodactylidae chromoproteins
WO2002070705A2 (en) * 2000-10-27 2002-09-12 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding them
EP1330524A2 (de) * 2000-10-30 2003-07-30 Lexicon Genetics Incorporated Humane 7tm-proteine und dafür kodierende polynukleotiden
US6645761B1 (en) * 2000-12-22 2003-11-11 Stratagene Humanized polynucleotide sequence encoding Renilla mulleri green fluorescent protein
US6969597B2 (en) * 2001-02-21 2005-11-29 Clontech Laboratories, Inc. Nucleic acids encoding non aggregating fluorescent proteins and methods for using the same
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CA2440560A1 (en) * 2001-03-07 2002-09-19 Xenogen Corporation Methods of screening for introduction of dna into a target cell
JP3929250B2 (ja) * 2001-03-08 2007-06-13 株式会社ルネサステクノロジ 半導体装置
WO2002077011A2 (en) * 2001-03-12 2002-10-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Oxidation-reduction sensitive green fluorescent protein variants
WO2002096924A1 (en) * 2001-05-25 2002-12-05 Clontech Laboratories, Inc. Kindling fluorescent proteins and methods for their use
JP3829252B2 (ja) 2001-06-08 2006-10-04 独立行政法人理化学研究所 蛍光蛋白質
US6780974B2 (en) * 2001-06-12 2004-08-24 Cellomics, Inc. Synthetic DNA encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
AU2002326589B2 (en) * 2001-08-07 2008-06-05 University Of Delaware Compositions and methods for the prevention and treatment of Huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US7150989B2 (en) 2001-08-10 2006-12-19 Cornell Research Foundation, Inc. Telomerase immortalized neural progenitor cells
ATE488585T1 (de) * 2001-08-27 2010-12-15 Syngenta Participations Ag Selbstprozessierende pflanzen und pflanzenteile
KR20040066788A (ko) 2001-08-31 2004-07-27 더 락커펠러 유니버시티 프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절
CA2461824A1 (en) * 2001-10-12 2003-04-17 Clontech Laboratories, Inc. Nucleic acids encoding linked chromo/fluorescent domains and methods for using the same
JP2005509420A (ja) * 2001-11-13 2005-04-14 クローンテック ラボラトリーズ インク． 新規発色団／蛍光発色団およびそれらの使用法
RU2330067C2 (ru) * 2001-12-19 2008-07-27 Дзе Юниверсити Оф Чикаго Полинуклеотид, кодирующий хромо- или флуоресцирующий мутантный полипептид, вектор экспрессии, клетка, способ получения хромо- или флуоресцирующего полипептида, набор для получения хромо- или флуоресцирующего полипептида, применение полипептида и применение полинуклеотида
CA2467084A1 (en) * 2001-12-26 2003-07-17 Clontech Laboratories, Inc. Mutant chromophores/fluorophores and methods for making and using the same
EP1474161A4 (de) * 2002-01-16 2005-06-29 Zyomyx Inc Durch engineering hergestellte bindungsproteine
DE60331422D1 (de) 2002-01-22 2010-04-08 Evrogen Ip Fluoreszierendes protein aus aequorea coerulescens und ihre verwendungen
US6918839B2 (en) * 2002-01-28 2005-07-19 The Boeing Company Damage tolerant shaft
US20040005301A1 (en) * 2002-02-12 2004-01-08 Goldman Steven A. Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
US7576065B2 (en) * 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
EP1572923A4 (de) * 2002-03-06 2007-10-31 Rigel Pharmaceuticals Inc Neues verfahren zur zuführung und intrazellulären synthese von sirna-molekülen
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US7262025B2 (en) * 2002-06-18 2007-08-28 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
EP1539786A4 (de) * 2002-07-10 2006-09-06 Stratagene California HUMANISIERTES, GRÜN FLUORESZIERENDES RENILLA RENIFORMIS-PROTEIN ALS GERüST
WO2004050829A2 (en) * 2002-08-20 2004-06-17 Aeras Global Tuberculosis Vaccine Foundation Recombinant double-stranded rna phage, and use of the same
EP1546329A4 (de) * 2002-09-13 2006-07-12 Univ Queensland Auf codontranslationseffizienz beruhendes genexpressionssystem
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2004042010A2 (en) * 2002-10-30 2004-05-21 University Of Tennessee Research Foundation Modified luciferase nucleic acids and methods of use
DE03779067T1 (de) 2002-11-12 2006-06-22 Zakrytoe Aktsionernoe Obschestvo "Evrogen" Fluoreszenzproteine und chromoproteine aus nicht-aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
US20050019925A1 (en) * 2002-11-14 2005-01-27 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
DE10255852B4 (de) * 2002-11-29 2006-06-22 Deutsches Institut für Ernährungsforschung Verfahren zur Expressionsveränderung von Polypeptiden in rekombinanten Expressionssystemen
US7413874B2 (en) * 2002-12-09 2008-08-19 University Of Miami Nucleic acid encoding fluorescent proteins from aquatic species
AU2003287115A1 (en) 2002-12-26 2004-07-22 Zakrytoe Aktsionernoe Obschestvo "Evrogen" Fluorescent proteins from copepoda species and methods for using same
US7083931B2 (en) * 2003-04-04 2006-08-01 Stratagene California Renilla GFP mutants with increased fluorescent intensity and spectral shift
EP1624748A4 (de) * 2003-05-08 2009-01-07 Health Research Inc Transgenes tiermodell für krebs- und stammzellen
US7160698B2 (en) * 2003-05-22 2007-01-09 University Of Florida Research Foundation, Inc. Fluorescent and colored proteins, and polynucleotides that encode these proteins
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
WO2005004798A2 (en) 2003-06-10 2005-01-20 The J. David Gladstone Institutes Methods for treating lentivirus infections
KR100577512B1 (ko) * 2003-06-16 2006-05-10 주식회사 바이오인프라 녹색 형광 단백질과 Ｂｆｌ-1의 융합단백질 또는 이를코딩하는 유전자를 포함하는 세포사멸을 유도하기 위한약학 조성물
US20050037409A1 (en) * 2003-07-29 2005-02-17 Kauvar Lawrence M. Translocation tagging
DE10336760A1 (de) * 2003-08-08 2005-03-03 Axaron Bioscience Ag Verfahren zur in vivo-Markierung definierter Zelltypen innerhalb eines Gewebeverbands
SI2325202T1 (sl) * 2003-08-28 2015-02-27 Superlab Far East Limited Uporabe interferonov s spremenjeno prostorsko strukturo
KR20060130009A (ko) * 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
JP4572320B2 (ja) * 2004-02-23 2010-11-04 財団法人大阪産業振興機構 組換えヒト細胞、ならびにその組換えヒト細胞を用いてヒト薬物代謝酵素の誘導および薬物代謝の少なくとも一方を評価する方法
US8953866B2 (en) 2004-03-16 2015-02-10 Amnis Corporation Method for imaging and differential analysis of cells
CA2598602A1 (en) 2004-03-16 2005-10-20 Amnis Corporation Image based quantitation of molecular translocation
JP4755174B2 (ja) 2004-04-07 2011-08-24 ザ ユニヴァーシティー オヴ シカゴ 単量体赤色蛍光タンパク質
AU2005287393A1 (en) * 2004-06-18 2006-03-30 The University Of Montana AAV mediated gene delivery to cochlear cells
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
US7728118B2 (en) * 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
EP2845865A1 (de) 2004-11-12 2015-03-11 Xencor Inc. FC-Varianten mit Veränderter Bindung zu FCRN
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
US7230080B2 (en) * 2005-02-16 2007-06-12 University Of Florida Research Foundation, Inc. Fluorescent and colored proteins, and polynucleotides that encode these proteins
CA2597317C (en) * 2005-03-09 2018-01-02 Guangwen Wei Uses of recombinant super-compound interferons
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
WO2007041251A2 (en) * 2005-09-30 2007-04-12 Montana State University System for detecting protein-protein interactions
EP2386564B1 (de) * 2005-10-01 2014-07-16 Charles Stout Regulierbare Fusionspromoter
US7417131B2 (en) * 2005-11-04 2008-08-26 Evrogen Joint Stock Company Modified green fluorescent proteins and methods for using same
US20090311664A1 (en) * 2005-12-22 2009-12-17 Yuman Fong Method for Detection of Cancer Cells Using Virus
EP1989303A2 (de) * 2006-02-27 2008-11-12 Edenspace System Corporation Energiepflanzen für verbessertes biokraftstoffrohmaterial
EA015925B1 (ru) * 2006-06-29 2011-12-30 ДСМ АйПи АССЕТС Б.В. Способ получения полипептидов
US20080004410A1 (en) * 2006-06-30 2008-01-03 Yu-Chin Lai Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
WO2008008284A2 (en) 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof
US8680235B2 (en) * 2006-09-22 2014-03-25 Stowers Institute For Medical Research Branchiostoma derived fluorescent proteins
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008112226A2 (en) * 2007-03-13 2008-09-18 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
WO2008118445A1 (en) * 2007-03-26 2008-10-02 Promega Corporation Methods to quench light from optical reactions
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2179037A4 (de) 2007-08-21 2010-12-22 Nodality Inc Diagnose-, prognose- und behandlungsverfahren
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
US20090081715A1 (en) * 2007-09-07 2009-03-26 Cobalt Technologies, Inc., A Delaware Corporation Engineered Light-Emitting Reporter Genes
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA3138078C (en) 2007-10-02 2024-02-13 Labrador Diagnostics Llc Modular point-of-care devices and uses thereof
US8679749B2 (en) * 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
EP3825329A1 (de) 2007-12-26 2021-05-26 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
CA2721076A1 (en) 2008-04-09 2009-10-15 Cobalt Technologies, Inc. Immobilized product tolerant microorganisms
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
JP5304275B2 (ja) * 2009-01-29 2013-10-02 Ｊｎｃ株式会社 アポクライティン−ｉｉをコードするコドン最適化核酸およびその使用方法
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EP2396343B1 (de) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
WO2010096510A2 (en) 2009-02-17 2010-08-26 Edenspace Systems Corporation Tempering of cellulosic biomass
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
CA2758542A1 (en) 2009-04-17 2010-10-21 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
TWI372183B (en) * 2009-05-05 2012-09-11 Nat Univ Tsing Hua Utilizing shield effect for dopamine detection and reagent development
US20120079627A1 (en) 2009-05-29 2012-03-29 Edenspace Systems Corporation Plant gene regulatory elements
WO2010151706A1 (en) 2009-06-26 2010-12-29 Cobalt Technologies, Inc. Integrated system and process for bioproduct production
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
US20120003639A1 (en) 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
FR2961375B1 (fr) 2010-06-16 2016-05-13 Inst De Rech Pour Le Dev (Ird) Surproduction d'acide jasmonique dans des plantes transgeniques
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
CN106290160A (zh) 2011-01-21 2017-01-04 提拉诺斯公司 样品使用最大化的系统和方法
WO2012155071A1 (en) 2011-05-12 2012-11-15 Gilead Biologics, Inc. Methods of identifying lysyl oxidase - like - 2 (loxl2) binding partners
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
EP2788384B1 (de) 2011-12-08 2017-08-09 Amgen Inc. Agonistische menschliche lcat-antigenbindende proteine und ihre verwendung in der therapie
FR2984076A1 (fr) 2011-12-15 2013-06-21 Inst Rech Developpement Ird Surproduction de jasmonates dans des plantes transgeniques
AU2012352429B2 (en) 2011-12-16 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US20150168416A1 (en) 2012-06-06 2015-06-18 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCs)
EP3539563A1 (de) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Für cd22 spezifischer antikörper und verfahren zur verwendung davon
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
WO2014028939A2 (en) 2012-08-17 2014-02-20 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
EP2895610B1 (de) 2012-09-13 2019-11-06 Indiana University Research and Technology Corporation Zusammensetzungen und systeme zur induzierung von krankheitsresistenz bei pflanzen und verfahren zu ihrer verwendung
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
SG11201507416WA (en) 2013-03-15 2015-10-29 Amgen Inc Human pac1 antibodies
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
EP3004167B1 (de) 2013-05-30 2018-07-25 Kiniksa Pharmaceuticals, Ltd. Oncostatin-m-rezeptor-antigenbindende proteine
ES2800827T3 (es) 2013-06-10 2021-01-04 Ipierian Inc Procedimientos de tratamiento de una tauopatía
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US11545241B1 (en) 2013-09-07 2023-01-03 Labrador Diagnostics Llc Systems and methods for analyte testing and data management
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
EA038994B1 (ru) 2013-11-27 2021-11-18 Айпириэн, Инк. Способы лечения таупатии
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3447493B1 (de) 2014-01-07 2020-05-13 Bioatla, LLC Protein-anzielende orthologe
EP4008726A1 (de) 2014-02-20 2022-06-08 Allergan, Inc. Antikörper der komplementkomponente c5
EP3110845A1 (de) 2014-02-27 2017-01-04 Allergan, Inc. Komplementfaktor-bb-antikörper
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
US10690661B2 (en) 2014-07-11 2020-06-23 Northwestern University Yeast-based biosensor
EP3172240A4 (de) * 2014-07-22 2018-04-18 The Regents of the University of California Endosomale escape-domänen für das einbringen von makromolekülen in zellen
AU2015294834B2 (en) 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
LT3850946T (lt) 2014-12-05 2024-01-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą ląstelės diferenciacijos klasterio 47 geną
RU2711729C2 (ru) 2014-12-09 2020-01-21 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274
AU2016219534B2 (en) 2015-02-09 2021-07-01 Massachusetts Institute Of Technology Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof
JP6907124B2 (ja) 2015-04-17 2021-07-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
US9920102B2 (en) 2015-05-15 2018-03-20 Albert Einstein College Of Medicine, Inc. Fusion tags for protein expression
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
US10285388B2 (en) 2015-05-29 2019-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
ES2842306T3 (es) 2015-09-02 2021-07-13 Immutep Sas Anticuerpos anti LAG-3
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CA3011359A1 (en) 2016-01-13 2017-07-20 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
SG11201806150RA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
WO2017136712A1 (en) 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CA3038548A1 (en) 2016-09-30 2018-04-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
US11280790B2 (en) * 2016-10-04 2022-03-22 Svar Life Science Ab System and products for improved quantification of ADCC activity
MX2019005256A (es) 2016-11-04 2019-08-05 Regeneron Pharma Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
SG10201914064QA (en) 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CA3052291A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
WO2018146549A1 (en) 2017-02-10 2018-08-16 Eutilex Co., Ltd. IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
CN110461871B (zh) 2017-02-16 2024-04-26 索纳特生物疗法公司 白蛋白结合结构域融合蛋白
ES2953875T3 (es) 2017-02-27 2023-11-16 Regeneron Pharma Modelos de retinosquisis en roedor
MX2019013142A (es) 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
CA3071852A1 (en) 2017-08-04 2019-02-07 Amgen Inc. Method of conjugation of cys-mabs
JP7430636B2 (ja) 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
SG11202004273YA (en) 2017-12-11 2020-06-29 Amgen Inc Continuous manufacturing process for bispecific antibody products
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
BR112020016306A2 (pt) 2018-02-12 2020-12-15 Curators Of The University Of Missouri Gene (saur) suprarregulado pequeno de auxina para o melhoramento da arquitetura do sistema radicular da planta, tolerância ao encharcamento, resistência à seca, e rendimento
IL305557A (en) 2018-06-14 2023-10-01 Regeneron Pharma Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
JP2021532140A (ja) 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
SG11202100987RA (en) 2018-08-03 2021-02-25 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3
JP2022500504A (ja) 2018-09-14 2022-01-04 プレリュード コーポレーションPrelude Corporation 浸潤性乳癌のリスクを有する対象の治療の選択方法
UY38393A (es) 2018-09-28 2020-03-31 Amgen Inc Anticuerpos contra bcma soluble
CA3114802A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
CA3120799A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
CN113544153A (zh) 2019-01-03 2021-10-22 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
MA56117A (fr) 2019-06-05 2022-04-13 Regeneron Pharma Animaux non humains ayant un répertoire de chaînes légères lambda limité exprimé à partir du locus kappa et leurs utilisations
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
BR102019017792A2 (pt) 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4121459A1 (de) 2020-03-19 2023-01-25 Amgen Inc. Antikörper gegen mucin 17 und verwendungen davon
MX2022014150A (es) 2020-05-11 2023-02-27 Invetx Inc Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso.
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
WO2022008488A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of slamf1 as a biomarker in colorectal cancer
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
WO2022013256A1 (en) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd160 as a biomarker in acute myeloid leukemia
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
JP2023548345A (ja) 2020-11-06 2023-11-16 アムジエン・インコーポレーテツド クリッピング率の低減した抗原結合ドメイン
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
WO2022125355A1 (en) 2020-12-07 2022-06-16 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
EP4281774A2 (de) 2021-01-20 2023-11-29 Nautilus Subsidiary, Inc. Verfahren zur quantifizierung von biomolekülen
EP4314078A1 (de) 2021-04-02 2024-02-07 Amgen Inc. Mageb2-bindende konstrukte
US20220331241A1 (en) 2021-04-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4416279A1 (de) 2021-10-14 2024-08-21 Asimov, Inc. Integrasen, landepadarchitekturen und manipulierte zellen damit
WO2023086822A2 (en) 2021-11-09 2023-05-19 Asimov Inc. Stable production systems for aav vector production
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024104551A1 (en) 2022-11-14 2024-05-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the population of slamf4+ ccr5+ effector memory cd4+ t cells as a biomarker in rheumatoid arthritis
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE400651T1 (de) * 1993-09-10 2008-07-15 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) * 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5625048A (en) * 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods

Also Published As

Publication number Publication date
CA2243088A1 (en) 1997-07-24
AU1750297A (en) 1997-08-11
US5968750A (en) 1999-10-19
ATE295416T1 (de) 2005-05-15
EP0874903A1 (de) 1998-11-04
JP2008086327A (ja) 2008-04-17
AU730842B2 (en) 2001-03-15
NZ330957A (en) 2000-06-23
WO1997026333A1 (en) 1997-07-24
JP2000503536A (ja) 2000-03-28
US5874304A (en) 1999-02-23
EP0874903B1 (de) 2005-05-11
CA2243088C (en) 2009-12-15
DE69733247T2 (de) 2006-01-19
JP4229469B2 (ja) 2009-02-25

Similar Documents

Publication Publication Date Title
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
ATE500323T1 (de) Subtilisin-variante
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
ATE389666T1 (de) Hohe expressionsrate von proteinen
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
DK0866720T3 (da) OB-protein til forögelse af mager kropsmasse
NO995182L (no) Pattedyrcytokinlignende faktor 7
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
IT8921243A0 (it) Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
FR2662698B1 (de)
ATE397081T1 (de) Erhöhte expression von proteinen mittels gfp
ATE233811T1 (de) Blutplaettchen-gpiiia p1a1 und -p1a2-epitope, ihre herstellung und verwendung
ATE265533T1 (de) Saeugetierchemokine
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE385805T1 (de) Neue peptide
DK0708831T4 (da) Celledensitetsforstærkede proteintyrosinphosphataser
Hwang et al. Involvement of Oxygen Radicals in the Low-Temperature Photoinhibition of Photosystem I
ATE412764T1 (de) Genetische transduktion von hämatopoietische vorläuferzellen
DK0887404T3 (da) Gen, som bibringer selektiv proliferationsaktivitet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition